CRISPR Therapeutics (CRSP) Tops Q4 EPS by 79c

CRISPR Therapeutics (NASDAQ: CRSP) reported Q4 EPS of ($0.44), $0.79 better than the analyst estimate of ($1.23). Revenue for the quarter came in at $35.69 million versus the consensus estimate of $7.63 million.

For earnings history and earnings-related data on CRISPR Therapeutics (CRSP) click here.

You May Also Be Interested In

• Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
• RBC Capital Reiterates Outperform Rating on Aviva PLC (AV:LN) (AVVIY)
• ICICI Bank (ICICIBC:IN) (IBN) PT Raised to INR2,000 at Goldman Sachs